in-vitro-tumor-cell-rechallenge-for-predictive-evaluation-chimeric

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

The field of chimeric antigen receptor (CAR) T cell therapy is rapidly advancing with improvements in CAR design, gene-engineering approaches and ...

City of Hope Beckman Research Institute and Medical Center

A patient with recurrent multifocal glioblastoma received chimeric antigen receptor (CAR)-engineered T cells targeting the tumor-associated antigen interleukin-13 receptor alpha 2 (IL13Rα2). Multiple infusions of CAR T cells were administered over 220 days through two intracranial delivery routes - infusions into the resected tumor cavity followed by infusions into the ventricular system. Intracranial infusions of IL13Rα2-targeted CAR T cells were not associated with any toxic effects of grade 3 or higher. After CAR T-cell treatment, regression of all intracranial and spinal tumors was observed, along with corresponding increases in levels of cytokines and immune cells in the cerebrospinal fluid. This clinical response continued for 7.5 months after the initiation of CAR T-cell therapy. (Funded by Gateway for Cancer Research and others; ClinicalTrials.gov number, NCT02208362 .).

Darya Alizadeh

Department of Hematology & Hematopoietic Cell Transplantation,
T Cell Therapeutics Research Laboratory,
Department of Hematology & Hematopoietic Cell Transplantation, T Cell Therapeutics Research Laboratory

City of Hope Beckman Research Institute and Medical Center

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Darya Alizadeh

.css-o250i3{font-size:18px;font-family:Open Sans,sans-serif;line-height:21.6px;}Department of Hematology & Hematopoietic Cell Transplantation,T Cell Therapeutics Research Laboratory,Department of Hematology & Hematopoietic Cell Transplantation, T Cell Therapeutics Research Laboratory

City of Hope Beckman Research Institute and Medical Center

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Department of Hematology & Hematopoietic Cell Transplantation,
T Cell Therapeutics Research Laboratory,
Department of Hematology & Hematopoietic Cell Transplantation, T Cell Therapeutics Research Laboratory